Medexus Pharmaceuticals Inc. (TSE:MDP) Receives Consensus Recommendation of “Strong Buy” from Analysts

Medexus Pharmaceuticals Inc. (TSE:MDP) has received an average recommendation of “Strong Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is C$5.58.

MDP has been the topic of several recent research reports. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday. Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a research report on Wednesday, January 8th. Stifel Nicolaus boosted their target price on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Finally, Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th.

Medexus Pharmaceuticals Stock Up 10.1 %

MDP opened at C$4.92 on Tuesday. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$5.56. The company has a market capitalization of C$120.69 million, a P/E ratio of 98.40 and a beta of 1.96. The stock’s fifty day moving average is C$3.25 and its two-hundred day moving average is C$2.72.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.